Re: Sarcopenia is a Poor Prognostic Factor of Castration-Resistant Prostate Cancer Treated with Docetaxel Therapy

被引：0
|
作者：
Griebling, Tomas L.
机构：
来源：
JOURNAL OF UROLOGY | 2020年 / 203卷 / 01期
关键词：
D O I：
10.1097/01.JU.0000604840.21681.4b
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：10 / 11
页数：2
相关论文
共 50 条
  • [31] Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer
    Kume, Haruki
    Kawai, Taketo
    Nagata, Masayoshi
    Azuma, Takeshi
    Miyazaki, Hideyo
    Suzuki, Motofumi
    Fujimura, Tetsuya
    Nakagawa, Tohru
    Fukuhara, Hiroshi
    Homma, Yukio
    MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (02) : 303 - 307
  • [32] Docetaxel with or without zoledronic acid for castration-resistant prostate cancer
    Yue Pan
    Haiyong Jin
    Wei Chen
    Zhixian Yu
    Tingyu Ye
    Yuancai Zheng
    Zhiliang Weng
    Feng Wang
    International Urology and Nephrology, 2014, 46 : 2319 - 2326
  • [33] Docetaxel with or without zoledronic acid for castration-resistant prostate cancer
    Pan, Yue
    Jin, Haiyong
    Chen, Wei
    Yu, Zhixian
    Ye, Tingyu
    Zheng, Yuancai
    Weng, Zhiliang
    Wang, Feng
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2014, 46 (12) : 2319 - 2326
  • [34] Docetaxel in combination with estramustine and prednisolone for castration-resistant prostate cancer
    Kuramoto, Tomomi
    Inagaki, Takeshi
    Fujii, Reona
    Sasaki, Yumiko
    Nishizawa, Satoshi
    Nanpo, Yoshihito
    Matusmura, Nagahide
    Kohjimoto, Yasuo
    Hara, Isao
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (05) : 890 - 897
  • [35] Management of metastatic castration-resistant prostate cancer following docetaxel
    Beuzeboc, Philippe
    Ropert, Stanislas
    Goldwasser, Francois
    Zerbib, Marc
    BULLETIN DU CANCER, 2012, 99 : S66 - S72
  • [36] Docetaxel in combination with estramustine and prednisolone for castration-resistant prostate cancer
    Tomomi Kuramoto
    Takeshi Inagaki
    Reona Fujii
    Yumiko Sasaki
    Satoshi Nishizawa
    Yoshihito Nanpo
    Nagahide Matusmura
    Yasuo Kohjimoto
    Isao Hara
    International Journal of Clinical Oncology, 2013, 18 : 890 - 897
  • [37] Pathophysiology and therapy of castration-resistant prostate cancer
    Merseburger, A. S.
    Kuczyk, M. A.
    Wolff, J. M.
    UROLOGE, 2013, 52 (02): : 219 - 225
  • [38] Key Notes on Pembrolizumab and Docetaxel Combination Therapy for Metastatic Castration-Resistant Prostate Cancer
    Thoman, Maxton E.
    Salari, Keyan
    EUROPEAN UROLOGY, 2022, 82 (01) : 31 - 33
  • [39] Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer
    Di Lorenzo, Giuseppe
    Buonerba, Carlo
    Faiella, Adriana
    Rescigno, Pasquale
    Rizzo, Mimma
    Autorino, Riccardo
    Perdona, Sisto
    Riccardi, Nando
    Scagliorini, Sarah
    Scognamiglio, Florinda
    Masala, Daniele
    Ferro, Matteo
    Palmieri, Giovannella
    Aieta, Michele
    Marinelli, Alfredo
    Altieri, Vincenzo
    De Placido, Sabino
    Carteni, Giacomo
    BJU INTERNATIONAL, 2011, 107 (02) : 234 - 239
  • [40] Satraplatin for the therapy of castration-resistant prostate cancer
    Sonpavde, Guru
    Sternberg, Cora N.
    FUTURE ONCOLOGY, 2009, 5 (07) : 931 - 940
12345